Market Place
Sourcing Support
InnoCare Doses 1st in Ph 3 TYK2 Inhibitor Trial for Atopic Dermatitis
14 Nov 2024 //
BUSINESSWIRE
InnoCare`s ICP-488 Meets Primary Endpoint In Psoriasis
09 Oct 2024 //
BUSINESSWIRE
InnoCare`s BCL2 Inhibitor ICP-248 Trial Approved for AML in China
18 Sep 2024 //
BUSINESSWIRE
InnoCare`s Orelabrutinib Data Presented At ESMO Congress 2024
13 Sep 2024 //
BUSINESSWIRE
InnoCare Releases 2024 Interim Results and Business Highlights
20 Aug 2024 //
BUSINESSWIRE
Zurletrectinib Shows Strong Activity Against NTRK Fusion-Positive Tumors
30 Jul 2024 //
BUSINESSWIRE
InnoCare Doses First Subject In US Trial Of TYK2 Inhibitor ICP-332
23 Jul 2024 //
BUSINESSWIRE
InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China
20 Jun 2024 //
BUSINESSWIRE
InnoCare Announces US FDA Clearance Of ICP-332 Clinical Trial
12 Jun 2024 //
BUSINESSWIRE
InnoCare Completes Psoriasis Phase 2 Trial Enrollment For ICP-488
15 May 2024 //
BUSINESSWIRE
InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
12 Mar 2024 //
BUSINESSWIRE
InnoCare Announces Clearance of Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
15 Jan 2024 //
BUSINESSWIRE
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27 Dec 2023 //
BUSINESSWIRE
InnoCare Appoints Xin Fu as Chief Financial Officer
17 Dec 2023 //
BUSINESSWIRE
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332
17 Dec 2023 //
BUSINESSWIRE
Data of InnoCare’s Oncology Pipelines Presented at the 65th Meeting of ASH
10 Dec 2023 //
BUSINESSWIRE
InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
26 Oct 2023 //
BUSINESSWIRE
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189
13 Sep 2023 //
BUSINESSWIRE
InnoCare Announces Approval of Trial of pan-TRK Inhibitor Zurletrectinib
25 Jul 2023 //
BUSINESSWIRE
InnoCare and ArriVent Announce Clinical Development Collaboration
13 Jul 2023 //
GLOBENEWSWIRE
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2
04 Jul 2023 //
BUSINESSWIRE
Latest Data of InnoCare`s Orelabrutinib Presented at the 17th (ICML)
15 Jun 2023 //
BUSINESSWIRE
Data of InnoCare’s Robust Pipelines Presented at the EHA
11 Jun 2023 //
BUSINESSWIRE
InnoCare Releases 2022 Annual Results and Business Highlights
27 Mar 2023 //
BUSINESSWIRE
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2
09 Mar 2023 //
BUSINESSWIRE
InnoCare and Keymed Jointly Announce Subject Dosed in Trial of CCR8 Monoclonal Antibody ICP-B05
23 Feb 2023 //
BUSINESSWIRE
Biogen CEO says company `lost its way,` cuts $125M MS partnership amid declining revenue
16 Feb 2023 //
ENDPTS
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
25 Jan 2023 //
BUSINESSWIRE
InnoCare to Present Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI
04 Jan 2023 //
BUSINESSWIRE
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide
28 Dec 2022 //
BIOSPACE
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide
27 Dec 2022 //
BUSINESSWIRE
InnoCare Announces Approval of HIBRUKA (Orelabrutinib)
22 Nov 2022 //
BUSINESSWIRE
InnoCare Releases 2022 Third Quarter Results
14 Nov 2022 //
BUSINESSWIRE
InnoCare Announces First Patient Dosed in Trial of pan-TRK Inhibitor ICP-723
31 Oct 2022 //
BUSINESSWIRE
InnoCare Completes Initial Public Offering on the STAR Market
20 Sep 2022 //
BUSINESSWIRE
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
12 Sep 2022 //
BUSINESSWIRE
InnoCare Announces 1st Patient Dosed in PII Trial of Tafasitamab & Lenalidomide
08 Sep 2022 //
BUSINESSWIRE
China NMPA grants priority review for InnoCare’s orelabrutinib for lymphoma
06 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
InnoCare`s BLA for Tafasitamab in Combination with Lenalidomide got Acceptence
30 Aug 2022 //
BUSINESSWIRE
InnoCare & Keymed Announce Approval of Trial of CCR8 Monoclonal Antibody CM369
23 Aug 2022 //
BUSINESSWIRE
InnoCare Releases 2022 Mid-Year Results and Business Highlights
21 Aug 2022 //
BUSINESSWIRE
InnoCare Announces Acceptance of Supplemental NDA for Orelabrutinib
12 Aug 2022 //
BUSINESSWIRE
InnoCare Announces 1st Subject Dosed in Clinical Trial of TYK2 JH2
01 Aug 2022 //
BUSINESSWIRE
InnoCare Announces First Prescription of Tafasitamab in Combo with Lenalidomide
21 Jul 2022 //
BUSINESSWIRE
InnoCare Announces Approval of Trial of Novel Targeted Protein Degrader ICP-490
06 Jul 2022 //
BUSINESSWIRE
InnoCare Begins Dosing in Trial of Novel SHP2 Allosteric Inhibitor ICP-189
21 Jun 2022 //
BUSINESSWIRE
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO
06 Jun 2022 //
BUSINESSWIRE
Latest Data of InnoCare’s Orelabrutinib for SLE at LBA Session of EULAR 2022
05 Jun 2022 //
BUSINESSWIRE
InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022
11 Apr 2022 //
BUSINESSWIRE
NMPA Approves InnoCare`s Trial of TYK2 JH2 Allosteric Inhibitor ICP-488
27 Mar 2022 //
PRNEWSWIRE
InnoCare Releases 2021 Annual Results and Business Highlights
22 Mar 2022 //
PRNEWSWIRE
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib
01 Mar 2022 //
PRNEWSWIRE
InnoCare Begins Dosing in Phase II Clinical Trial Using Orelabrutinib for ITP
22 Feb 2022 //
PRNEWSWIRE
InnoCare and Keymed Jointly Announce Dosing in Trial of CM355
18 Jan 2022 //
BIOSPACE
InnoCare to Attend Upcoming Investor Conferences
06 Jan 2022 //
PRNEWSWIRE
InnoCare to Present Orelabrutinib Data atthe Upcoming 63rd Annual Meeting of ASH
09 Nov 2021 //
PRNEWSWIRE
InnoCare`s Clinical Trial of ICP-189 gets approval in China
19 Oct 2021 //
PRNEWSWIRE
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CM355
17 Sep 2021 //
PRNEWSWIRE
InnoCare Announces Clearance of Clinical Trial of pan-TRK Inhibitor ICP-723
30 Aug 2021 //
PRNEWSWIRE
